Vasculopathy-related cutaneous lesions and intrahepatic cholestasis as a synchronous manifestations in COVID-19 patient: case report
Gastroenterology and Hepatology from Bed to Bench,
20 September 2020
Nowadays, Covid-19 pneumonia, makes many globally concerns. World health organization has reported many mortalities in all around the world, due to covid-19 disease. therefore, recognizing new cases of covid-19 is crucial during this pandemic. Many studies showed that covid-19 has broad spectrum of signs and symptoms including GI and cutaneous manifestations. Previous literatures reported liver enzyme changes and diarrhoea as a common GI manifestation of covid-19. however, there are few reports about COVID-19 cutaneous and liver synchronous involvement. Additionally, there are few reports about intrahepatic cholestasis in those patients. in this article, we attempted to introduced a COVID-19 confirmed case with vasculopathy-related cutaneous manifestation and liver cholestasis.
- cutaneous lesion
(WHO) WHO. Coronavirus disease (COVID-19) Situation Report– 122 22,may,2020 [Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7194618/pdf/main.pdf.
Torkian P, Ramezani N, Kiani P, Bax MR, Akhlaghpoor S. Common CT Findings of Novel Coronavirus Disease 2019 (COVID-19): A Case Series. Cureus. 2020;12(3):e7434-e.
Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr. 2020;87(4):281-6.
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708-20.
Suchonwanit P, Leerunyakul K, Kositkuljorn C. Cutaneous manifestations in COVID-19: Lessons learned from current evidence. Journal of the American Academy of Dermatology. 2020.
Hormati A, Shahhamzeh A, Afifian M, Khodadust F, Ahmadpour S. Can COVID-19 present unusual GI symptoms? J Microbiol Immunol Infect. 2020:S1684-182(20)30080-3.
Moazzami B, Razavi-Khorasani N, Dooghaie Moghadam A, Farokhi E, Rezaei N. COVID-19 and telemedicine: Immediate action required for maintaining healthcare providers well-being. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2020;126:104345-.
Fu L, Wang B, Yuan T, Chen X, Ao Y, Fitzpatrick T, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis. J Infect. 2020;80(6):656-65.
Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. Journal of the European Academy of Dermatology and Venereology : JEADV. 2020.
Castelnovo L, Capelli F, Tamburello A, Maria Faggioli P, Mazzone A. Symmetric cutaneous vasculitis in COVID-19 pneumonia. Journal of the European Academy of Dermatology and Venereology.n/a(n/a).
Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clin Immunol. 2020;214:108393-.
Qureshi WA. Intrahepatic cholestatic syndromes: pathogenesis, clinical features and management. Dig Dis. 1999;17(1):49-59.
Li J, Fan J-G. Characteristics and Mechanism of Liver Injury in 2019 Coronavirus Disease. J Clin Transl Hepatol. 2020;8(1):13-7.
Delemos AS, Friedman LS. Systemic causes of cholestasis. Clin Liver Dis. 2013;17(2):301-17.
Omrani-Nava V, Maleki I, Ahmadi A, Moosazadeh M, Hedayatizadeh-Omran A, Roozbeh F, et al. Evaluation of Hepatic Enzymes Changes and Association with Prognosis in COVID-19 Patients. Hepat Mon. 2020;20(4):e103179.
Al-Azzawi H, Patel R, Sood G, Kapoor S. Plasmapheresis for Refractory Pruritus due to Drug-Induced Cholestasis. Case Rep Gastroenterol. 2017;10(3):814-8.
Keith P, Day M, Perkins L, Moyer L, Hewitt K, Wells A. A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19. Crit Care. 2020;24(1):128-.
- Abstract Viewed: 0 times